1380600-06-5Relevant academic research and scientific papers
PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS VIA FAST-FLOW SYNTHESIS
-
Page/Page column 88, (2019/04/16)
Provided herein are processes for preparing an oligomer (e.g., a morpholino oligomer). The synthetic processes described herein may be advantageous to scaling up oligomer synthesis while maintaining overall yield and purity of a synthesized oligomer.
EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY
-
, (2018/07/22)
Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 53 skipping are described.
EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY
-
, (2018/07/15)
Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 51 skipping are described.
PROCESSES FOR PREPARING OLIGOMERS
-
, (2017/12/29)
Provided herein are processes for preparing an oligomer (e.g., a morpholino oligomer). The synthetic processes described herein may be advantageous to scaling up oligomersynthesis while maintaining overall yield and purity of a synthesized oligomer.
ANTISENSE-INDUCED EXON EXCLUSION IN MYOSTATIN
-
Page/Page column 85, (2016/10/04)
The present disclosure relates to antisense oligomers and related compositions and methods for decreasing the expression of functional human myostatin and methods for treating muscular dystrophy and related disorders and more specifically relates to induc
FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF
-
Paragraph 0947, (2014/11/13)
Functionally-modified oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3′ and/or 5′-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or corr
OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
-
, (2011/12/14)
Oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3'' and/or 5''-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.
